Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect a balanced acknowledgment of the study's findings, including comments like 'weight loss outcomes were less than expected' and references to patient adherence rates, with tone and word choice emphasizing real-world challenges, which demonstrates moderate agreement and engagement. The mention of clinical implications indicates a perceived meaningful impact on patient care and treatment strategies.
Most discussions acknowledge that the study's findings highlight challenges with real-world adherence and weight loss outcomes, aligning with the article's conclusions.
The posts show moderate interest, with some expressing curiosity about the actual adherence rates and clinical implications, though few delve deeply into the details.
Participants reference the study's data, such as the percentage of patients achieving weight loss or discontinuing medication, indicating a reasonable level of engagement.
The discussions suggest that the article influences opinions about treatment effectiveness in real-world settings, emphasizing the importance of adherence and support in management strategies.
◆GLP-1受容体作動薬の効果 イギリスで2型糖尿病患者（BMIの中央値は41.2）にGLP-1RAを投与をした研究。 5％以上減量した人の割合は、1年後には33.4％、2年後では43.5％であった。 「BMJ Open Diabetes Research & Care」2022年1月 https://t.co/FxWfgzZuHu
@thanksevrybody1 イギリスでBMIも高い2型糖尿病患者さんへのGLP-1投与のデザインにはなりますが、 https://t.co/wlDs6AVpxS 5％以上減量した人の割合が1年後には33.4％、2年後では43.5％というデータがあります。 健常人でも長い期間の投与で少ない食事量に慣れる期間が必要なのではないかと考えてます。
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (open access) https://t.co/z4bcfWjd7t #MetabolicSyndrome #Obesity #Diabetes #InsulinResistance #weightloss
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
Menos de lo esperado por los ensayos clínicos. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like ... https://t.co/3lvvKqcb48
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK https://t.co/s4NvajKeHb
This study examines how patients with type 2 diabetes in the UK stick to and benefit from GLP1 receptor agonists. About 54% achieved at least 5% weight loss at 12 and 24 months, but discontinuation was common…
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
◆GLP-1受容体作動薬の効果 イギリスで2型糖尿病患者（BMIの中央値は41.2）にGLP-1RAを投与をした研究。 5％以上減量した人の割合は、1年後には33.4％、2年後では43.5％であった。 「BMJ Open Diabetes Research & Care」2022年1月 https://t.co/FxWfgzZuHu
@thanksevrybody1 イギリスでBMIも高い2型糖尿病患者さんへのGLP-1投与のデザインにはなりますが、 https://t.co/wlDs6AVpxS 5％以上減量した人の割合が1年後には33.4％、2年後では43.5％というデータがあります。 健常人でも長い期間の投与で少ない食事量に慣れる期間が必要なのではないかと考えてます。
Menos de lo esperado por los ensayos clínicos. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like ... https://t.co/3lvvKqcb48
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (open access) https://t.co/z4bcfWjd7t #MetabolicSyndrome #Obesity #Diabetes #InsulinResistance #weightloss
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK https://t.co/s4NvajKeHb